# Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/information-requests-and-discipline-review-letters-under-the-generic-drug-user-fee-amendments-guidance-for-industry/791723ae-658a-431c-8b44-6ba50a528579

> FDA guidance document: Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry. Issue date: October 05, 2022. Get complete insights and analysis.

---

## Details

- Title: Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-10-05
- Last Changed: 2023-01-11
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-6752">FDA-2017-D-6752</a>

## Related Documents

- [Assessing User Fees Under the Biosimilar User Fee Amendments of 2022:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-biosimilar-user-fee-amendments-of-2022-guidance-for-industry/4fbb7da7-e7da-4ffb-a835-53f0fa1a9dda)
- [Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022](https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2022/a1bfde05-8672-4537-9ef7-bdf6377a9f3b)
- [ANDA Submissions – Prior Approval Supplements Under GDUFA:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-prior-approval-supplements-under-gdufa-guidance-for-industry/433ffd43-857c-4bec-84e3-acc6a271a04c)